Stock Screener App

Frei -

Installieren

2.12

0.95% 0.02

after-market

Handel nachbörslich: 2.10 -0.02 -0.94%

Silexion Therapeutics Corp (SLXN)

Überblick Nachrichten Preisverlauf Forum Prognose

Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten

Can Silexion Therapeutics Corp Equity Warrant stock sustain free cash flow growthJuly 2025 Opening Moves & Fast Gain Swing Alerts - ulpravda.ru

Can Silexion Therapeutics Corp Equity Warrant stock beat market expectations this quarterRecession Risk & Fast Exit Strategy with Risk Control - ulpravda.ru

Dividend Watch: Will Silexion Therapeutics Corp stock deliver strong dividend growthPortfolio Risk Summary & Fast Moving Market Watchlists - ulpravda.ru

Why Silexion Therapeutics Corp Equity Warrant stock attracts high net worth investorsFit and Size Notes & quick comparison of popular models - ulpravda.ru

Is Silexion Therapeutics Corp stock a buy for dividend growthJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - ulpravda.ru

Why retail investors favor Silexion Therapeutics Corp stockQuarterly Market Review & Free High Accuracy Swing Entry Alerts - ulpravda.ru

How strong is Silexion Therapeutics Corp stock revenue growthProduct Launch & Entry Point Confirmation Signals - ulpravda.ru

Will Silexion Therapeutics Corp stock deliver strong dividend growthPortfolio Risk Summary & Fast Moving Market Watchlists - ulpravda.ru

What momentum indicators show for Silexion Therapeutics Corp Equity Warrant stockMarket Performance Recap & Free Long-Term Investment Growth Plans - ulpravda.ru

Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsJuly 2025 Spike Watch & Daily Entry Point Trade Alerts - ulpravda.ru

Can Silexion Therapeutics Corp stock weather global recession2025 Price Action Summary & Short-Term High Return Strategies - ulpravda.ru

Signal Recap: What technical signals suggest for Silexion Therapeutics Corp stockWeekly Market Report & Consistent Growth Equity Picks - ulpravda.ru

Will Silexion Therapeutics Corp stock outperform Dow Jones indexTrade Entry Summary & Community Driven Trade Alerts - ulpravda.ru

Silexion Therapeutics CorpOrdinary Shares (NQ: SLXN - FinancialContent

Silexion outlines 2026 plans after transformational 2025 progress - TipRanks

Silexion Therapeutics Corp Highlights 2025 Achievements and 2026 Milestones - TradingView — Track All Markets

Silexion Therapeutics' Cancer Drug to Enter Human Trials in Early 2026 - MarketScreener

Silexion Therapeutics Reports Promising Preclinical Results for SIL204 in KRAS-Driven Cancers and Plans Phase 2/3 Trial Initiation for 2026 - Quiver Quantitative

Silexion Therapeutics Releases CEO Letter to Shareholders - GlobeNewswire

Cash per share of Silexion Therapeutics Corp Warrant – NASDAQ:SLXNW - TradingView — Track All Markets

Merger Talk: Is Silexion Therapeutics Corp Equity Warrant stock trading at a premium valuation2025 Top Decliners & Daily Volume Surge Signals - moha.gov.vn

Risk Hedge: Will Silexion Therapeutics Corp stock deliver strong dividend growth2025 Market Overview & Safe Capital Growth Stock Tips - moha.gov.vn

Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsJuly 2025 Retail & Free Technical Pattern Based Buy Signals - Улправда

Can Silexion Therapeutics Corp Equity Warrant stock hit record highs againJuly 2025 Weekly Recap & Daily Chart Pattern Signal Reports - Улправда

Will Silexion Therapeutics Corp Equity Warrant stock pay special dividendsTrade Exit Report & Weekly Top Performers Watchlists - DonanımHaber

How Silexion Therapeutics Corp stock compares to growth peersQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - DonanımHaber

Risk Analysis: Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsPortfolio Risk Report & High Conviction Trade Alerts - Улправда

Treasury Yields: How strong is Silexion Therapeutics Corp stock revenue growthWeekly Trade Report & AI Based Buy and Sell Signals - DonanımHaber

Silexion Therapeutics (NASDAQ:SLXN) Upgraded at Zacks Research - Defense World

Can Silexion Therapeutics Corp stock sustain free cash flow growth2025 Year in Review & Fast Exit/Entry Strategy Plans - Улправда

Gains Report: Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsJuly 2025 Recap & AI Driven Stock Price Forecasts - Улправда

Stop Loss: Can Silexion Therapeutics Corp Equity Warrant stock hit record highs again - Улправда

Silexion Therapeutics submits Phase 2/3 trial application - MSN

Silexion Therapeutics Submits Phase 2/3 Trial Application - TipRanks

Silexion submits Phase 2/3 trial application to Israel for SIL204 - TipRanks

Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 - TradingView — Track All Markets

Silexion Therapeutics Advances Regulatory Submission for Phase 2/3 Trial of SIL204 in Pancreatic Cancer - Quiver Quantitative

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for Sil204 in Locally Advanced Pancreatic Cancer - marketscreener.com

Silexion Therapeutics (NASDAQ:SLXN) Now Covered by Litchfield Hills Research - Defense World

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer - The Manila Times

Silexion Therapeutics initiated with a buy at Litchfield Hills - MSN

Silexion Therapeutics initiated with a Buy at Litchfield Hills - TipRanks

Bearish Setup: Is Silexion Therapeutics Corp Equity Warrant stock recession proof2025 Momentum Check & AI Forecasted Entry/Exit Points - moha.gov.vn

Silexion Shares Decline After Update on German Regulatory Review - MSN

Silexion Therapeutics (SLXNW) Stock Analysis Report | Financials & Insights - Benzinga

How buybacks impact Silexion Therapeutics Corp stock valueProfit Target & Intraday High Probability Setup Alerts - Newser

Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment - TipRanks

Silexion Therapeutics drops 18%, prices $5M share offering - MSN

Silexion receives positive feedback from German Health Authority for SIL204 - TipRanks

Silexion Therapeutics (SLXN) Stock Analysis Report | Financials & Insights - Benzinga

Silexion stock falls after receiving German regulatory feedback By Investing.com - Investing.com Canada

Silexion stock falls after receiving German regulatory feedback - Investing.com

INCY

$106.87

0.90%

GMAB

$34.26

1.87%

RVMD

$118.64

10.48%

BNTX

$99.85

1.01%

ONC

$337.89

5.47%

INSM

$175.97

3.35%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters